I want to get continuous structured data on new clinical trial protocols, regulatory submission requirements, and outcome measures from global research registers, regulatory body websites, and academic publications.
A shared demo template. Read-only preview of what would be monitored in a real pilot.
Pilot Configuration
Pilot Phase (Scoped Evaluation)
Up to 12 weeksTypical scope: multi-country, weekly updates, multiple categories
- Real data from real sources
- Live dashboards or export feeds
- Validate scope, refresh cadence, quality
- Fixed price, no ongoing commitment
Most teams start here to validate fit before expanding.
Now, schedule a short call below to confirm scope and start the pilot, or build something new.
or email us at paul@jsonify.co
Data sources are the websites and apps where information will be collected from. These can be changed or expanded at any time. This is turned into data rows.
| id | Source | TrialID | Title | Phase | Intervention | PrimaryOutcome | StartDate | LastUpdated | Status | Location | SampleSize | ||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 |
|
NCT05812345 | Randomized Phase 2 Trial of ABX-201 vs Placebo in Treatment-Naïve Moderate COVID-25 | Phase 2 | ABX-201 oral 200 mg daily | Change in WHO Clinical Progression Scale at Day 14 | Jan 15, 2026 | Feb 2, 2026 | Recruiting | United States, Canada | 240 | ||
| 2 |
|
EUCTR2026-000123-45 | Open-label Phase 3 Study of OncoVax-P in HER2-negative Metastatic Breast Cancer | Phase 3 | OncoVax-P IV every 3 weeks + standard chemo | Progression-free survival at 12 months | Dec 1, 2025 | Feb 3, 2026 | Active, not recruiting | Germany, France, Spain | 640 | ||
| 3 |
|
WHO-ITH-2026-001 | Cluster RCT of Community-based Malaria Prophylaxis in Rural Uganda | Phase 4 | Monthly DP (dihydroartemisinin–piperaquine) sachets | Incidence of symptomatic malaria episodes per 1000 person-years | Nov 20, 2025 | Feb 1, 2026 | Ongoing | Uganda | 4800 | ||
| 4 |
|
CTR2026-78901 | Phase 1/2 Study of Lenti-CRISPR Therapy for Sickle Cell Disease | Phase 1/2 | Ex vivo Lenti-CRISPR autologous infusion | Percentage of patients with hemoglobin >9 g/dL at 6 months | Dec 10, 2025 | Feb 4, 2026 | Recruiting | United Kingdom, Netherlands | 48 | ||
| 5 |
|
MHRA-CT-2026-012 | Randomized Controlled Trial of RSV Vaccine NVX-RSV in Adults ≥60 | Phase 3 | NVX-RSV single IM dose vs placebo | Vaccine efficacy against laboratory-confirmed RSV LRTI at 6 months | Dec 18, 2025 | Feb 3, 2026 | Recruiting | United Kingdom | 12000 | ||
| 6 |
|
AT-TRIAL-2026-77 | Comparative Effectiveness of Telemedicine Behavioral Therapy for Opioid Use Disorder | Phase 3 | Weekly telemedicine CBT vs in-person CBT | Retention in treatment at 24 weeks | Dec 5, 2025 | Feb 2, 2026 | Active, not recruiting | United States | 900 | ||
| 7 |
|
RG-2026-PRO-09 | Pilot Trial of Novel Inhaled Insulin Formulation in Type 1 Diabetes | Phase 1 | Inhaled insulin micro‑aerosol, dose-escalation | Safety: rate of hypoglycemia episodes within 28 days | Jan 20, 2026 | Feb 4, 2026 | Recruiting | Australia | 36 | ||
| 8 |
|
TLC-CLIN-2026-02 | Multicentre Trial of High-dose IV Vitamin C in Severe Sepsis | Phase 3 | IV Vitamin C 6 g q6h for 4 days + standard care | 28-day all-cause mortality | Nov 30, 2025 | Feb 1, 2026 | Ongoing | Multi-country (UK, India, Brazil) | 1500 | ||
| 9 |
|
OUP-TR-2026-11 | Randomized Study of Omega-3 Supplementation for Prevention of Postoperative Atrial Fibrillation | Phase 4 | Omega-3 2 g daily vs placebo for 30 days | Incidence of AF within 30 days post-cardiac surgery | Dec 22, 2025 | Feb 3, 2026 | Recruiting | United States | 1200 | ||
| 10 |
|
SD-RES-2026-334 | Phase 2 Trial of Oral TYK2 Inhibitor for Moderate-to-Severe Psoriasis | Phase 2 | TYK2 inhibitor 10 mg daily | Percent achieving PASI75 at Week 12 | Jan 10, 2026 | Feb 2, 2026 | Recruiting | Brazil, Mexico | 240 | ||
| 11 |
|
BMC-CLIN-2026-05 | Double-blind Trial of Probiotic Regimen to Prevent Antibiotic-associated Diarrhea in Elderly | Phase 4 | Multi-strain probiotic BID during antibiotics | Incidence of AAD within 30 days | Dec 28, 2025 | Feb 4, 2026 | Recruiting | United Kingdom | 800 | ||
| 12 |
|
NCT05900111 | Adaptive Platform Trial of Broad-spectrum Antivirals for Emerging Respiratory Viruses | Phase 2/3 | Arm A: Broad-spectrum antiviral X; Arm B: Standard care | Time to sustained clinical recovery (7-day symptom-free) | Jan 25, 2026 | Feb 3, 2026 | Recruiting | Global (US, UK, India, South Africa) | 2400 | ||
| 13 |
|
WVU-NCTU-2026-09 | Feasibility Study of Wearable ECG Monitoring to Detect Postoperative AF | Phase 2 | Wearable continuous ECG patch vs standard telemetry | Detection rate of AF within 7 days post-op | Jan 12, 2026 | Feb 1, 2026 | Ongoing | United States | 300 | ||
| 14 |
|
CTR2026-99800 | Phase 2b Study of Oral GLP-1 Receptor Agonist in Nonalcoholic Steatohepatitis (NASH) | Phase 2b | GLP-1 RA 5 mg SC weekly vs placebo | Change in liver fat fraction by MRI at 24 weeks | Dec 15, 2025 | Feb 4, 2026 | Recruiting | Italy, Spain | 420 | ||
| 15 |
|
MHRA-CT-2026-033 | Randomized Trial of Short-course Antibiotics for Uncomplicated UTIs in Women | Phase 3 | 3-day vs 7-day antibiotic regimen (nitrofurantoin) | Clinical cure at Day 14 | Jan 5, 2026 | Feb 2, 2026 | Recruiting | United Kingdom | 1500 | ||
| 16 |
|
WHO-VAX-2026-012 | Phase 2 Study of Novel Dengue Vaccine Candidate in Adolescents | Phase 2 | Dengue tetravalent recombinant vaccine, 2 doses IM | Neutralizing antibody GMT at Day 56 | Dec 2, 2025 | Feb 3, 2026 | Active, not recruiting | Indonesia, Philippines | 900 | ||
| 17 | thelan cet.com | TLC-ONC-2026-08 | Neoadjuvant Immunotherapy with Anti-PD-1 + Chemo in Triple-negative Breast Cancer | Phase 2 | Anti-PD-1 IV q3w x4 + standard chemo | Pathologic complete response rate at surgery | Dec 7, 2025 | Feb 1, 2026 | Recruiting | United States, Canada, UK | 180 | ||
| 18 |
|
RG-2026-ENDO-21 | Randomized Trial of Low-dose Estradiol Vaginal Ring for Genitourinary Syndrome of Menopause | Phase 3 | Estradiol ring 12-week vs placebo | Change in GSM symptom score at 12 weeks | Jan 18, 2026 | Feb 4, 2026 | Recruiting | Germany, Sweden | 480 | ||
| 19 |
|
OUP-DERM-2026-03 | Topical Small-molecule JAK Inhibitor Cream for Atopic Dermatitis | Phase 2 | JAK inhibitor 2% cream BID vs vehicle | EASI score reduction at Week 8 | Jan 8, 2026 | Feb 2, 2026 | Recruiting | United States, Canada | 300 | ||
| 20 |
|
SD-NEURO-2026-17 | Phase 3 Trial of Subcutaneous Anti-Tau Antibody in Early Alzheimer's Disease | Phase 3 | Anti-Tau mAb 600 mg SC q4w | Change in CDR-SB at 18 months | Nov 25, 2025 | Feb 3, 2026 | Active, not recruiting | United States, Japan, South Korea | 2600 | ||
| 21 |
|
BMC-PSY-2026-02 | Digital CBT App vs Waitlist for Adolescent Anxiety: Pragmatic Trial | Phase 3 | Digital CBT app access for 12 weeks | Change in GAD-7 score at 12 weeks | Jan 22, 2026 | Feb 4, 2026 | Recruiting | United Kingdom | 1200 | ||
| 22 |
|
NCT05890077 | Dose-ranging Phase 1 Study of Novel Anticoagulant FXIa Inhibitor | Phase 1 | FXIa inhibitor oral tablets, single ascending doses | Dose-limiting adverse events within 28 days | Jan 30, 2026 | Feb 4, 2026 | Recruiting | United States | 72 | ||
| 23 |
|
CTR2026-45012 | Randomized Study of Early Mobilization Protocol After Hip Fracture Repair | Phase 4 | Enhanced mobilization protocol vs standard physiotherapy | Time to independent ambulation within 30 days | Dec 20, 2025 | Feb 2, 2026 | Ongoing | Sweden, Norway | 560 | ||
| 24 |
|
MHRA-CT-2026-078 | Vaccine Immunogenicity Study of Seasonal Influenza Formulation in Healthcare Workers | Phase 4 | Quadrivalent influenza vaccine annual dose | Seroconversion rate at Day 28 | Jan 10, 2026 | Feb 1, 2026 | Recruiting | United Kingdom | 2000 | ||
| 25 |
|
WHO-PRT-2026-005 | Water, Sanitation and Hygiene (WASH) Intervention Trial to Reduce Childhood Diarrhea | Phase 4 | Community WASH package vs standard practice | Incidence rate of diarrheal episodes in children <5 over 12 months | Dec 5, 2025 | Feb 3, 2026 | Ongoing | Bangladesh | 7200 | ||
| 26 |
|
AT-ONC-2026-19 | Registry-linked Trial of CAR-T Toxicity Mitigation Strategies | Phase 2 | Early IL-6 blockade protocol vs standard supportive care | Incidence of Grade ≥3 cytokine release syndrome within 30 days | Jan 14, 2026 | Feb 4, 2026 | Recruiting | United States | 360 | ||
| 27 |
|
RG-IMMU-2026-14 | First-in-Human Study of Intranasal Monoclonal Antibody for Seasonal Allergy | Phase 1 | Intranasal mAb spray, single dose cohort | Local tolerability and symptom scores at 7 days | Jan 5, 2026 | Feb 2, 2026 | Recruiting | Canada | 48 | ||
| 28 |
|
TLC-INF-2026-06 | Cluster Randomized Trial of Antibiotic Stewardship in Neonatal Units | Phase 3 | Stewardship bundle vs usual care | Antibiotic days per 1000 patient-days over 6 months | Nov 28, 2025 | Feb 1, 2026 | Ongoing | South Africa, Kenya | 4200 | ||
| 29 |
|
OUP-CARD-2026-07 | Randomized Trial of Remote Ischemic Conditioning to Reduce Myocardial Injury | Phase 2 | RIPC device perioperative vs sham | Troponin rise >5x baseline within 48 hours | Jan 2, 2026 | Feb 3, 2026 | Recruiting | United Kingdom | 540 | ||
| 30 |
|
SD-ENDO-2026-29 | Phase 2 Trial of Oral SGLT3 Inhibitor in Diabetic Kidney Disease | Phase 2 | SGLT3 inhibitor 10 mg daily | Change in eGFR slope at 52 weeks | Dec 12, 2025 | Feb 4, 2026 | Active, not recruiting | United States, Canada, Australia | 600 | ||
| Looking for more? Great news − this is just a small sample. Jsonify production workflows process anywhere from tens of thousands to millions of real data rows per run! | |||||||||||||
Filters
Total New Clinical Trial Protocols
Top Countries by Clinical Trials Registered
Latest Clinical Trials Updates
| Protocol ID | Trial Title | Status | Phase | Submission Date |
|---|---|---|---|---|
| NCT04512345 | A Study of Drug A in Patients with Condition B | Recruiting | Phase 2 | 2026-01-15 |
| NCT04567890 | Evaluation of Drug C for Condition D Treatment | Completed | Phase 3 | 2026-01-22 |
| NCT04678901 | Long-term Effects of Treatment E in Disease F | Active, not recruiting | Phase 1 | 2026-01-10 |
| NCT04789012 | Comparative Study of Drug G and H in Adults | Recruiting | Phase 2 | 2026-01-29 |
| NCT04890123 | Investigation of Vaccine J for Infection K | Pending | Phase 3 | 2026-02-01 |
Total Regulatory Submissions
Distribution of Clinical Trials by Phase
Recent Regulatory Changes
| Date | Source | Protocol Title | Regulatory Change |
|---|---|---|---|
| 2026-01-30 |
|
A Study on the Efficacy of Drug A | New safety reporting requirements implemented |
| 2026-01-25 |
|
Phase III Trial for Vaccine B | Revised submission guidelines for clinical trials |
| 2026-01-20 |
|
Global Initiative for Treatment C | Updated outcome measures for reporting effectiveness |
| 2026-01-15 |
|
Clinical Trial on Drug D | Changes to informed consent procedures |
| 2026-01-10 |
|
Evaluation of Device E | New regulatory framework introduced for CE marking |
| 2026-01-05 |
|
Longitudinal Study on Condition F | Altered data transparency requirements |
| 2026-01-01 |
|
Trial of Therapy G in Pediatric Patients | Mandatory interim results reporting established |
| 2025-12-28 |
|
Investigation of Agent H's Safety | New pharmacovigilance standards set |
Total Outcome Measures Identified
Regulatory Submissions by Type
Key Observations on Clinical Trial Trends
Trends in New Clinical Trials Over Time
Most Common Outcome Measures
Cumulative Outcomes Measures Over Time
Loading...
Loading...
Radar continuously monitors your selected web sources and alerts you the moment something changes.
+7
Data connections determine where the collected data will be delivered. You can add, remove, or change connections at any time.